Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126.

Tumours derived from DLD-1 colon adenocarcinoma cells, transfected to either overexpress inducible nitric oxide synthase (clone iNOS-19) or with empty vector (pBAN2R), were utilised to test the hypothesis that tumour expression of iNOS (a) increases tumour angiogenesis and (b) modulates the anti-tumour activity of the vascular disrupting agent ZD6126. Overexpression of iNOS by clone iNOS-19 cells and murine xenografts was confirmed by the Griess assay and western blot analysis respectively. Clone iNOS-19 tumours grew more rapidly than pBAN2R tumours. Tumour perfusion, assessed by Hoechst 33342 uptake, was significantly greater in the clone iNOS-19 tumours (P < 0.001). A significant reduction in the perfusion of only the pBAN2R tumours, compared with control, was obtained 24 h after treatment with an intermediate dose of 100 mg/kg ZD6126 (P < 0.001), whereas 200 mg/kg significantly reduced the perfusion of both tumour types (P < 0.001). Whilst pBAN2R tumour necrosis increased in a dose-dependent manner, significant at 100 and 200 mg/kg ZD6126 (P < 0.05), intermediate doses did not induce a similar degree of necrosis in clone iNOS-19 tumours. A significant reduction in splenic perfusion was found 24 h after treatment with 100 mg/kg ZD6126, primarily associated with the red pulp. Overexpression of iNOS increases tumour growth, the degree of functionally perfused vasculature and angiogenesis, and also confers resistance to the vascular disrupting agent ZD6126.

• Publication year

  2006

• Venue

  Microvascular Research

• Publication date

  2006-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.MVR.2006.01.004PMID 16530791
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.

  2005cited by this paper
• The role of early expression of inducible nitric oxide synthase in human breast cancer.

  2005cited by this paper
• Disrupting tumour blood vessels

  2005cited by this paper
• Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma.

  2005cited by this paper
• Evaluation of tissue perfusion (tumor, spleen, heart) in mice after administration of AVE8062, a tumor vascular-targeting agent

  2004cited by this paper
• Vascular‐targeting therapies for treatment of malignant disease

  2004cited by this paper
• Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126

  2004cited by this paper
• High interstitial fluid pressure — an obstacle in cancer therapy

  2004cited by this paper
• Nitric oxide differentially regulates pro‐ and anti‐angiogenic markers in DLD‐1 colon carcinoma cells

  2004cited by this paper
• Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo.

  2004cited by this paper
• Angiogenesis in health and disease

  2003cited by this paper
• Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging

  2003cited by this paper
• Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging.

  2003cited by this paper
• Vascular-targeting activity of ZD6126, a novel tubulin-binding agent.

  2003cited by this paper
• Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.

  2003cited by this paper
• Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate.

  2003cited by this paper
• Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response.

  2003cited by this paper
• Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.

  2002cited by this paper
• Enhancement of vascular targeting by inhibitors of nitric oxide synthase.

  2002cited by this paper
• Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.

  2002cited by this paper
• High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow.

  2002cited by this paper
• Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126.

  2002cited by this paper
• Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice.

  2002cited by this paper
• Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis

  2002cited by this paper
• Glioma tumourgenicity is decreased by iNOS knockout: experimental studies using the C6 striatal implantation glioma model

  2002cited by this paper
• ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.

  2002cited by this paper
• Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide

  2000cited by this paper
• Vascular-specific growth factors and blood vessel formation

  2000cited by this paper
• Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors.

  1999cited by this paper
• Animal Model Nitric Oxide Synthase Inhibition by N G -Nitro- L Arginine Methyl Ester Inhibits Tumor-Induced Angiogenesis in Mammary Tumors

  1999cited by this paper
• Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

  1999cited by this paper
• Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer.

  1998cited by this paper
• Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression.

  1998cited by this paper
• The multifaceted roles of nitric oxide in cancer.

  1998cited by this paper
• p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells

  1998cited by this paper
• Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions.

  1997cited by this paper
• Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells.

  1997cited by this paper
• Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis.

  1997cited by this paper
• Role of nitric oxide in growth of solid tumours: a balancing act.

  1997cited by this paper
• Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor.

  1997cited by this paper
• Nitric oxide stimulates the activity of a 72-kDa neutral matrix metalloproteinase in cultured rat mesangial cells.

  1996cited by this paper
• Application of an image analysis system to the quantitation of tumor perfusion and vascularity in human glioma xenografts.

  1995cited by this paper
• Roles of nitric oxide in tumor growth.

  1995cited by this paper
• Nitric oxide synthase activity in human breast cancer.

  1995cited by this paper
• Ischemia reperfusion injury in tumors: the role of oxygen radicals and nitric oxide.

  1995cited by this paper
• Expression of nitric oxide synthase in human central nervous system tumors.

  1995cited by this paper
• Nitric oxide synthase activity in human gynecological cancer.

  1994cited by this paper
• Nitric oxide modulates microvascular permeability.

  1992cited by this paper
• Nitric oxide: physiology, pathophysiology, and pharmacology.

  1991cited by this paper
• Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy.

  1990cited by this paper
• Spontaneous cyclic contractions of the capillary wall in vivo, impeding red cell flow: a quantitative analysis. Evidence for endothelial contractility.

  1988cited by this paper
• The Microcirculatory Society Eugene M. Landis award lecture. Microcirculation of the spleen: new concepts, new challenges.

  1987cited by this paper
• Cell selection from a murine tumour using the fluorescent probe Hoechst 33342.

  1985cited by this paper
• Landis Award Lecture. The myogenic response and the microcirculation.

  1977cited by this paper

• Targeted microbubbles carrying lipid-oil-Nanodroplets for ultrasound-triggered delivery of the hydrophobic drug, Combretastatin A4.

  2021cites this paper
• Rapid stromal remodeling by short‐term VEGFR2 inhibition increases chemotherapy delivery in esophagogastric adenocarcinoma

  2019cites this paper
• A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1

  2017cites this paper
• Suppression of ERK1/2 and hypoxia pathways by four Phyllanthus species inhibits metastasis of human breast cancer cells

  2016cites this paper
• Investigating the role of tumour cell derived iNOS on tumour growth and vasculature in vivo using a tetracycline regulated expression system

  2016cites this paper
• Rol del óxido nítrico en la progresión del cáncer de vejiga

  2016cites this paper
• TROSATIVE STRESS PARAMETERS IN COLON CANCER TUMOR, ADJACENT AND HEALTHY TISSUE

  2016cites this paper
• Cell metabolism under microenvironmental low oxygen tension levels in stemness, proliferation and pluripotency.

  2015cites this paper
• Detecting microvascular changes in the mouse spleen using optical computed tomography

  2015cites this paper
• Gr-1+CD11b+ cells facilitate Lewis lung cancer recurrence by enhancing neovasculature after local irradiation

  2014cites this paper
• Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography

  2014cites this paper
• Inhibition of Raf-MEK-ERK and Hypoxia pathways by Phyllanthus prevents metastasis in human lung (A549) cancer cell line

  2013cites this paper
• NOS‐2 signaling and cancer therapy

  2012cites this paper
• NO (nitric oxide): the ring master.

  2011cites this paper
• The influence of nitric oxide synthase 2 on cutaneous wound angiogenesis

  2011cites this paper
• Angiogenic signaling aberrantly induced by tumor hypoxia.

  2011cites this paper
• Combination Therapy with Chemotherapy and VDAs

  2010cites this paper
• Gene Environment Interactions and Vascular Lesions

  2010cites this paper
• Targeting the tumour microenvironment : characterizing the anti-vascular effects of the hypoxic cytotoxin tirapazamine

  2010cites this paper
• Silibinin Exerts Sustained Growth Suppressive Effect against Human Colon Carcinoma SW480 Xenograft by Targeting Multiple Signaling Molecules

  2010cites this paper
• The role of tumour-derived iNOS in tumour progression and angiogenesis

  2010cites this paper
• Both host and graft vessels contribute to revascularization of xenografted human ovarian tissue in a murine model.

  2010cites this paper
• Nitric oxide synthase 2 gene polymorphisms are associated with prostatic volume in Korean men with benign prostatic hyperplasia.

  2010cites this paper
• Potential cell signalling mechanisms involved in differential placental angiogenesis in mild and severe pre-eclampsia.

  2009cites this paper
• Exploring vascular dysfunction caused by tirapazamine.

  2008cites this paper
• Biological effects of HBV X protein on hepatocellular carcinogenesis in association with cellular factors

  2008cites this paper
• Effect of Inducible Nitric Oxide Synthase on Cerebral Blood Flow after Experimental Traumatic Brain Injury in Mice

  2008cites this paper
• Nitric Oxide in Tumor Angiogenesis

  2008cites this paper
• Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126.

  2007cites this paper
• The effects of tumor‐derived platelet‐derived growth factor on vascular morphology and function in vivo revealed by susceptibility MRI

  2007cites this paper
• Inducible nitric oxide synthase (iNOS) mediates the early increase of blood supply (EIBS) in colon carcinogenesis

  2007cites this paper
• Hypoxia: A key regulator of angiogenesis in cancer

  2007cites this paper